Invo Bioscience
INVO Bioscience (NASDAQ: IVOB) is a publicly traded fertility device and services company that markets the proprietary INVOcell intravaginal culture device, a lower-cost alternative to traditional IVF, and operates fertility clinics under the INVO Fertility brand serving patients seeking assisted reproductive technology.
- Company typePublic
- Founded2009
- HeadquartersSarasota, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Invo Bioscience does
INVO Bioscience Inc. (NASDAQ: IVOB) is a publicly traded, Sarasota, Florida-based fertility technology and services company that develops and commercializes the proprietary INVOcell intravaginal culture (IVC) medical device. INVOcell enables fertilization and early embryo development to occur inside the woman's body instead of in an embryology laboratory, positioning the procedure as a more affordable, less infrastructure-intensive alternative to traditional in vitro fertilization. The company holds a registered INVOcell® trademark covering the device brand and describes the technology as a novel method architecture distinct from standard IVF.
The business operates two revenue streams. The first is the sale and distribution of the INVOcell device to fertility clinics and reproductive healthcare providers for use in intravaginal culture procedures. The second is direct-to-consumer fertility treatment services delivered through company-owned clinics operated under the INVO Fertility brand, including via the recently acquired Wisconsin Fertility Institute. Customers split between (a) couples and individuals seeking affordable assisted reproductive technology treatment and (b) clinics/providers that purchase the device, with a stated hybrid segmentation approach.
INVO pursues a clinic-acquisition growth strategy and has tapped public equity markets repeatedly to fund expansion: $4.0 million in October 2021, $3.0 million in March 2023, and $4.5 million in August 2023. The company is small (11–50 employees), headquartered at 5582 Broadcast Court, Sarasota, FL, and runs marketing primarily through its corporate website, press releases, and investor relations channels.
Invo Bioscience firmographics
Firmographics- Name
- Invo Bioscience
- Legal name
- INVO Bioscience Inc.
- Website
- https://invobioscience.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- INVO Bioscience (NASDAQ: IVOB) is a publicly traded fertility device and services company that markets the proprietary INVOcell intravaginal culture device, a lower-cost alternative to traditional IVF, and operates fertility clinics under the INVO Fertility brand serving patients seeking assisted reproductive technology.
- Ownership category
- akta.pro rank
Invo Bioscience industry classification
Industry- Product category
- Reproductive Health Medical Devices
- NAICS
- Ambulatory Health Care Services (621), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
- akta.pro secondary industries
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
Keywords
Where Invo Bioscience is headquartered
LocationHeadquarters
- HQ city
- Sarasota
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Invo Bioscience business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Fertility Treatment Services (Clinic Operations): Revenue generated from operating fertility clinics that provide INVOcell-based treatments and other fertility services to patients. The acquisition of Wisconsin Fertility Institute expanded these operations.
- INVOcell Medical Device Sales: Revenue from the sale and distribution of the proprietary INVOcell medical device to fertility clinics and healthcare providers for use in intravaginal culture procedures.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Invo Bioscience product offering
Product offeringCore offering
INVO Bioscience develops and commercializes the INVOcell intravaginal culture (IVC) medical device, a proprietary system that enables in-vivo fertilization as a lower-cost, less infrastructure-intensive alternative to conventional in-vitro fertilization (IVF). The company also operates fertility clinics under the INVO Fertility brand that deliver fertility treatments to patients using its proprietary device and related reproductive technologies.
Product overview
INVO Bioscience offers a unified product centered around the INVOcell medical device, which is a proprietary intravaginal culture (IVC) system that allows fertilization and early embryo development to occur inside the woman's body. The company operates a network of fertility clinics under the INVO Fertility brand, integrating the INVOcell device with clinical services to provide more accessible and affordable fertility treatments.
Differentiator
Problem solved
Functional benefit
Brands
- INVOcell: Proprietary intravaginal culture (IVC) device that allows fertilization and early embryo development to take place within the woman's body, enhancing clinical efficiency and reducing costs of fertility treatments.
Products and services
- INVOcell Proprietary intravaginal culture (IVC) medical device that enables in-vivo fertilization as a lower-cost, more accessible alternative to traditional IVF; sold to fertility clinics and reproductive medicine centers worldwide.
- INVO Fertility Clinic Services Fertility treatment services delivered through company-owned fertility clinics operating under the INVO Fertility brand, using the INVOcell device and related reproductive technologies. Includes the Wisconsin Fertility Institute acquired in 2023.
Quantifiable outcome
- Reduced cost of fertility treatment compared to traditional IVF
Companies that use Invo Bioscience
Customer profileSegments2 records
Ideal customer profiles2 records
Invo Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Invo Bioscience partnerships and signals
Strategic signalScale indicators4 records
Recent moves4 records
Expansion highlights4 records
Invo Bioscience competitors and assessment
Company assessmentDirect peers
- CooperSurgical: CooperSurgical is a global medical device company serving the IVF and reproductive health market with a portfolio of ART devices, consumables and media. It directly competes with INVOcell in supplying fertility clinics with proprietary ART products, making it the closest comparables on the device side.
- Vitrolife: Vitrolife develops and sells media, devices and consumables for assisted reproductive technology, targeting IVF clinics with products used in embryo culture and handling. Overlap with INVOcell is direct on the device-and-consumable dimension of fertility treatment delivery.
- Prelude Fertility: Prelude Fertility is a fertility clinic network built through acquisition and partnership with reproductive endocrinologists. Its clinic-network acquisition playbook mirrors INVO's strategy of acquiring established fertility practices and rolling them into a branded network.
- Genea Biomedx: Genea Biomedx designs and manufactures ART devices and software for IVF clinics, including culture and incubation systems. Like INVOcell, it competes by offering clinics proprietary hardware that improves IVF lab workflows and outcomes.
Emerging players
- Progyny: Progyny is a fertility benefits management platform partnering with employers to provide IVF coverage through partner clinics. It is thematically aligned with INVO's mission to expand access to fertility care by lowering cost and reimbursement friction for patients seeking IVF.
Broad incumbents
- CCRM Fertility: CCRM is one of the largest US fertility clinic networks, performing conventional IVF and ancillary services across multiple states. It is comparable to INVO Fertility's owned-clinic strategy at much greater scale, illustrating both the addressable expansion path and the scale gap INVO must close.
- Ferring Pharmaceuticals: Ferring Pharmaceuticals is a large specialty pharmaceutical company with a leading reproductive health portfolio covering fertility treatments and obstetrics. It competes with INVOcell-adjacent therapies as an incumbent reproductive-health supplier rather than as a direct IVF device competitor.
- Shady Grove Fertility: Shady Grove Fertility operates a large multi-site fertility clinic network offering IVF and ART services across the United States. It represents the scaled incumbent clinic model that INVO's acquisition-driven INVO Fertility network is being built to emulate.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Invo Bioscience social profiles
Digital presenceInvo Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invo Bioscience leadership team
Management profileNumber of profiles
Profiles6 records
Invo Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Invo Bioscience funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invo Bioscience M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invo Bioscience
What does Invo Bioscience do?
INVO Bioscience develops and commercializes the INVOcell intravaginal culture (IVC) medical device, a proprietary system that enables in-vivo fertilization as a lower-cost, less infrastructure-intensive alternative to conventional in-vitro fertilization (IVF). The company also operates fertility clinics under the INVO Fertility brand that deliver fertility treatments to patients using its proprietary device and related reproductive technologies.
Is Invo Bioscience a public or private company?
Invo Bioscience is a public company. It is classified as public and is currently operating.
When was Invo Bioscience founded?
Invo Bioscience was founded in 2009. It employs 11 to 50 people.
Where is Invo Bioscience based?
Invo Bioscience is headquartered in Sarasota, United States, in the North America region.
How does Invo Bioscience make money?
Two revenue lines are on record. Fertility Treatment Services (Clinic Operations) is the primary driver. The others are INVOcell Medical Device Sales.
Who are Invo Bioscience's main competitors?
Direct peers on record are CooperSurgical, Vitrolife, Prelude Fertility and Genea Biomedx. Progyny is listed as an emerging player. Broad incumbents are CCRM Fertility, Ferring Pharmaceuticals and Shady Grove Fertility.
Does Invo Bioscience have an API?
No public API is recorded for Invo Bioscience.
What industry is Invo Bioscience in?
Invo Bioscience's product category is Reproductive Health Medical Devices. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 621 and its SIC code is 3841.